Details of the Drug

General Information of Drug (ID: DM5KD99)

Drug Name
Narsoplimab
Indication
Disease Entry ICD 11 Status REF
IgA nephropathy MF8Y Phase 3 [1]
Thrombotic microangiopathy 3B65 Phase 2 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DTB64R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mannan-binding lectin serine protease-2 (MASP2) TTR01E9 MASP2_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03608033) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT02222545) A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies. U.S.National Institutes of Health.
3 Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022 Aug 1;40(22):2447-2457.